Scarica l'app Stockscreener
105.87
0.10%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Biontech Se Adr Borsa (BNTX) Ultime notizie
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider - GlobeNewswire Inc.
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - The Globe and Mail
BioNTech (NASDAQ:BNTX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? - Finviz
Leerink downgrades BioNTech to “market perform” after 24% share rally - Investing.com
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer - TipRanks
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech's Strategic Pivot Gains Momentum with Key Oncology Milestones () - aktiencheck.de
BioNTech SE (BNTX): A Bull Case Theory - Finviz
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
Goldman Sachs upgrades BioNTech stock to Buy on oncology potential - Investing.com
SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It - Chartmill
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan - Yahoo Finance
BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial - TipRanks
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - Finviz
BioNTech Finalizes CureVac Acquisition, Shifts Focus to Integration () - aktiencheck.de
BioNTech: CN Considers to Approve Use of BioNTech Vaccine for Foreigners in CN - AASTOCKS.com
Scientists Question Pfizer, BioNTech's Vaccine Effectiveness - AASTOCKS.com
BioNTech, Pfizer See Covid Vaccine Capacity Rise to 3B Doses Next Yr - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition By Investing.com - Investing.com South Africa
FOSUN PHARMA Pairs with BioNTech to Supply BioNTech Vaccine to Germans in CN - AASTOCKS.com
1.77%
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):